drugset / Trial / NCT01511237

Perinatal Antiretroviral Intensification for PMTCT of HIV in Late Comers

NCT01511237

NaSingle-groupOpen-labelPrevention

Summary

The purpose is to evaluate the efficacy of maternal and infant perinatal antiretroviral prophylaxis intensification for the prevention of mother-to-child intrapartum transmission of HIV-1 in women receiving less than 8 weeks of antiretroviral prophylaxis during pregnancy.

Timeline

Start
2011-12
Primary completion
2015-06
Completion
2017-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Lamivudine Other / unclassified 2 mg/kg
Subject Lamivudine Other / unclassified 150 mg
Subject Nevirapine Small molecule 2 mg/kg
Subject Nevirapine Small molecule 4 mg/kg
Subject Nevirapine Small molecule 200 mg
Subject Zidovudine Small molecule 2 mg/kg
Subject Zidovudine Small molecule 3 mg/kg
Subject Zidovudine Small molecule 4 mg/kg
Subject Zidovudine Small molecule 300 mg